Han Joo Chae
Chief Business and Technology Officer · Oncosoft

Han Joo Chae

채한주

Medical AI matters only when it clears regulatory review, earns clinicians' trust, and reaches patients worldwide. As a technologist turned business leader, I build the partnerships, channels, and teams that take it there.

LinkedIn Scholar Email
$1B+
Long-term contracts secured
7 countries
Markets cleared or entered (Oncosoft)
20+
Hospitals in Korea (Oncosoft)
FDA / CE
Regulated launches led
Professional portrait
Clinical & research
Mayo ClinicUChicago MedicineYonsei Cancer CenterSamsung Medical Center
Commercial
GenXRT (US)Anzai Medical (Japan)OPUS (Chile)AstraZeneca Korea
Spoke at
AAPM Int'l SymposiumSOCHIRA (Chile)Google Cloud Startup SummitAWS Public Sector SummitNaverSamsung SSDCKAIST
Featured in
Google Cloud CustomersChosun Biz

About

Medical AI executive leading global business at Oncosoft, where I head the Global Business Division and drive expansion of AI radiation-oncology software across the US, Japan, Southeast Asia, and Latin America. I come from the technical side: I have built AI organizations from zero and taken products from prototype to regulated launch (FDA, CE, MFDS). At ROKIT Healthcare, I drove the commercial cycle from MVP to $1B+ in long-term contracts across the US, India, Turkey, the Middle East, and Latin America.

Global Business DevelopmentGlobal Go-to-MarketStrategic PartnershipsRegulatory (FDA/CE/MFDS)Medical AIAI Agents in Radiation OncologyComputer VisionMachine LearningHuman-Computer Interaction
Education
Seoul National University
Ph.D., Computer Science and Engineering
Human-Computer Interaction Lab
2015–2020
Carnegie Mellon University
M.S. & B.S., Electrical and Computer Engineering
B.S. with University Honors
2005–2010

Impact

Now · Current Role

Taking AI Radiation Oncology Global

Oncosoft · Chief Business and Technology Officer · 2024–present

As Chief Business and Technology Officer, I lead Oncosoft's Global Business Division, taking an end-to-end AI platform for radiation oncology from regulatory clearance to clinical adoption across the US, Japan, Southeast Asia, and Latin America.

Oncosoft — overview
6 countries
Regulatory clearances
20+
Hospitals in Korea
1st
Korean-developed carbon-ion TPS
~1 min
Major-organ auto-contouring
Regulatory clearances
Korea (MFDS)2022.02US (FDA)2025.02Japan2025.04Singapore2025.10Brazil2025.12OncoPlan · Korea (MFDS)2026.08Indonesia2026.10
Problem

Radiation therapy planning still depends on manual contouring of organs and tumors: slow, variable between clinicians, and a bottleneck to treating more patients. For AI to fix that worldwide, it has to clear each market's regulators and reach clinics through channels they already trust.

Approach

OncoStudio auto-contours organs-at-risk and tumors, major organs in about a minute, inside existing PACS, TPS, and EMR workflows. It anchors a platform with OncoFlow (workflow), OncoPlan (particle-therapy planning), and OncoAgent, a guideline-aware AI agent published at MICCAI 2026. My division turns that platform into market access: country-by-country regulatory entry, distribution and industry partnerships, government R&D programs and IP, and clinical AI deployment engineers who support adoption on site.

Impact

Cleared in six countries (Korea, US FDA 510(k), Japan, Singapore, Brazil, Indonesia), distributed in Chile through exclusive distributor OPUS, and used in 20+ hospitals in Korea. Mayo Clinic Florida is a customer under a 2025 solution supply agreement and a clinical validation partner; GenXRT is our first US commercial partner; Anzai Medical is the exclusive distributor in Japan. In particle therapy, OncoPlan was cleared by the MFDS in 2026 as the first carbon-ion treatment planning system developed by a Korean company, with Yonsei Cancer Center as technology transfer and joint R&D partner for carbon-ion planning and Samsung Medical Center as joint R&D partner for proton therapy validation.

OncoStudio — AI auto-contouring of organs and tumors on CT/MR
Demonstrating OncoStudio to visiting clinicians at the Oncosoft booth, AAPM 2026
Demonstrating OncoStudio to visiting clinicians at the Oncosoft booth, AAPM 2026
Meeting clinicians and partners at a global oncology conference
Meeting clinicians and partners at a global oncology conference
Receiving the International Symposium Award — 5th KSMP-JSMP-KAMPiNA Joint Symposium at AAPM, 2025
Receiving the International Symposium Award — 5th KSMP-JSMP-KAMPiNA Joint Symposium at AAPM, 2025
With the Oncosoft team on-site
With the Oncosoft team on-site
Mayo Clinic FloridaUChicago MedicineYonsei Cancer CenterSamsung Medical CenterGachon Gil Medical CenterProton Therapy SingaporeGenXRTAnzai MedicalOPUS (Chile)AstraZeneca KoreaParagon Care KoreaTerapet
Oncosoft ↗Paper — MICCAI 2026 ↗
Flagship Career Impact · 2020–2023

AI Cloud Platform for 3D-Bioprinted Wound Regeneration

ROKIT Healthcare · CAIO & Vice President · 2020–2023

An AI platform that turns a single tablet photo of a wound into a ready-to-print 3D patch model in seconds — then bio-prints it at the point of care to treat diabetic foot ulcers, deployed across the US, Asia, the Middle East, and Latin America.

ROKIT Healthcare — overview
$1B+
Long-term contracts
FDA + CE
Regulatory clearance
0→15
AI team built
~30 sec
Photo → printable 3D model
Problem

Personalized regenerative patches require precise scanning, CAD modeling, and bioprinting — work that a surgical team anywhere in the world cannot realistically do at the point of care. To reach patients globally, the hard part had to disappear into software.

Approach

We built an AI platform (AiD Regen) that, from a single tablet RGB-D photo, segments the wound, reconstructs its 3D surface, and generates a ready-to-print 3D model in about 30 seconds. Production-grade MLOps on Google Cloud (Vertex AI, GKE) delivers identical quality at any clinical site — no on-site AI specialist required.

Impact

Founded and scaled the AI department from zero to 15, achieved both FDA and CE clearance, and drove the full commercial cycle from MVP to $1B+ in long-term contracts across the US, India, Turkey, the Middle East, and Latin America. Launched on AWS in 6 months, then migrated to Google Cloud in 3 — the work became a featured Google Cloud customer story.

Technology overview — CVPR 2022 (wound segmentation & 3D reconstruction)
Wound capture → AI segmentation & 3D reconstruction
Wound capture → AI segmentation & 3D reconstruction
Personalized 3D-bioprinted regeneration patch
Personalized 3D-bioprinted regeneration patch
Point-of-care application in the operating room
Point-of-care application in the operating room
Google CloudAWS
Google Cloud customer story ↗Interview — Chosun Biz ↗Paper — CVPR 2022 ↗

Ventures & Research

Kai Health — product
Medical AI

AI Embryo Assessment

Kai Health · 2023–2024

Led AI diagnostic R&D for embryo assessment to MFDS (Korean FDA) clinical-trial approval, and rebuilt the product lifecycle to cut release cycles from ~2 months to 2–3 weeks.

DiagnosticsRegulatoryMLOps
Research roots

AR / HCI research at SNU & CMU

Seoul National University · Carnegie Mellon · 2007–2020

A decade of human-computer interaction and augmented-reality research — IoT-device interaction in AR, 3D interaction techniques, and mobile sensing — published at ACM and IEEE venues including UIST and CHI. The technical foundation behind the products above.

Experience

Oncosoft

Nov 2024 — Present
Seoul, Korea
Chief Business and Technology OfficerSep 2026 — Present
  • Lead the Global Business Division (Business Development, Programs & IP, Business Strategy), owning international expansion, channel and industry partnerships, government R&D programs, and IP strategy.
  • Pair business development with clinical AI deployment engineers who support hospital adoption on site.
CTO & Head of Global BusinessSep 2025 — Aug 2026
  • Led 20+ staff across R&D and global sales in Seoul and the US, securing Oncosoft's first commercial customers in the US and Japan and new clearances in Singapore and Brazil.
CTONov 2024 — Aug 2025
  • Led R&D through OncoStudio's FDA 510(k) clearance and Japanese certification, and supported a solution supply agreement with Mayo Clinic Florida, Oncosoft's first US revenue.

CTO

Nov 2023 — Oct 2024
Kai Health · Seoul, Korea
  • Led a 10+ member R&D team and established a structured product development lifecycle, reducing release cycles from ~2 months to 2–3 weeks through overlapping, parallelized workflows.
  • Elevated AI model accuracy and reliability by enforcing data integrity standards and advancing model architecture, culminating in MFDS (Korean FDA) clinical trial approval.

CAIO & Vice President

Oct 2020 — Aug 2023
ROKIT Healthcare · Seoul, Korea
  • Founded and scaled the AI department from zero to 15 members, leading the development of an AI-powered cloud platform for 3D bioprinted wound regeneration targeting diabetic foot ulcers (DFU).
  • Drove the full commercial cycle from MVP to $1B+ in long-term contracts across the US, India, Turkey, the Middle East, and Latin America, achieving both FDA and CE clearance for the solution.
  • Launched the AI cloud service on AWS in 6 months, then migrated to Google Cloud under a strategic partnership, establishing production-grade MLOps infrastructure in 3 months to support global commercial deployment.

PM, Doctoral Researcher

May 2016 — Apr 2020
HCI Lab @ Seoul National University · Seoul, Korea
  • Led and completed 4-year AR/MR research projects for Samsung Research, securing grants and publishing top-tier conference papers (UIST, CHI).

Software Developer

Oct 2014 — Dec 2015
Bluegg (startup) · Seoul, Korea
  • Developed Android and web applications for a social donation campaign platform.

UX Researcher

Aug 2010 — Dec 2013
Samsung Electronics · Suwon, Korea
  • Designed interfaces for mobile, tablet, TV, and smartwatch, developing prototypes for proof-of-concept across convergence scenarios.

Intern, HCI Development Team

Jun 2009 — Aug 2009
Samsung R&D Center Silicon Valley · San Jose, CA
  • Created a mobile 3D interface using sensors and image processing; resulting work was recognized with a Samsung Best Paper Award and a granted US patent.

Speaking & Teaching

Speaking on stage — conference photo
Invited talks
Teaching

Research & Patents

Full list on Google Scholar →

Granted patents — 8 invention families · 27 grants
  • US9672483B2Method of providing activity notification and device thereof7 grants2017–2026
  • US9629120B2Method and apparatus for providing notification11 grants2017–2024
  • US10374648B2Wearable device for transmitting a message comprising strings associated with a state of a user2 grants2019–2021
  • US10540013B2Method of performing function of device and device for performing the method2 grants2020
  • US10123064B2Content providing method and device2 grants2018–2020
  • US10020835B2Wearable device and method of transmitting message from the same2018
  • US9338620B2Method and apparatus for executing alarm with respect to missed received call for mobile communication terminal2016
  • US8310537B2Detecting ego-motion on a mobile device displaying three-dimensional content2012

Awards & Honors

Press & Media

Contact

Email me
Email me LinkedIn Google Scholar